The Discounted Cash Flow (DCF) valuation of Erytech Pharma SA (ERYP.PA) is (7.51) EUR. With the latest stock price at 0.50 EUR, the upside of Erytech Pharma SA based on DCF is -1604.9%.
Based on the latest price of 0.50 EUR and our DCF valuation, Erytech Pharma SA (ERYP.PA) is a sell. selling ERYP.PA stocks now will result in a potential gain of 1604.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.2% - 7.3% | 6.3% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (71.21) - (3.78) | (7.51) |
| Upside | -14370.0% - -857.1% | -1604.9% |